Keros Therapeutics (KROS) Stock Analysis & Winston Score

Keros Therapeutics is a clinical-stage biotechnology company focused on developing drugs that treat diseases related to the TGF-beta protein pathway, which controls how the body grows muscle, bone, and red blood cells. Its lead drug candidates target conditions like anemia, muscle-wasting diseases, and rare blood disorders such as myelodysplastic syndromes. The company's main customers are patients with serious, often hard-to-treat diseases that have few existing treatment options. Keros does not yet sell any approved products, so it earns no meaningful product revenue. Instead, it funds its research through equity raises, partnerships, and grants — a common model for early-stage biotech companies. It operates primarily in the United States and had a market cap of roughly $300 million as of mid-2026. The company's biggest risk is clinical failure: if its drug candidates do not prove safe and effective in trials, it could run out of cash before reaching the market, which is a real possibility given its deeply negative operating margins.